Sage shares surge as depression drug succeeds in mid-stage trial

(Reuters) – Drug developer Sage Therapeutics Inc’s shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply